Bony metastases: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
== Differential Diagnosis == |
== Differential Diagnosis == |
||
− | * Osteoblastic lesions |
+ | * Osteoblastic (sclerotic) lesions, with deposition of new bone |
− | ** |
+ | **[[Prostate cancer]] |
** [[Carcinoid tumour]] |
** [[Carcinoid tumour]] |
||
** [[Small cell lung cancer]] |
** [[Small cell lung cancer]] |
||
** [[Hodgkin lymphoma]] |
** [[Hodgkin lymphoma]] |
||
+ | ** [[Medulloblastoma]] |
||
− | * Osteolytic lesions |
||
+ | * Osteolytic lesions, with destruction of normal bone |
||
− | ** |
+ | **[[Renal cell carcinoma]] |
** [[Melanoma]] |
** [[Melanoma]] |
||
** [[Multiple myeloma]] |
** [[Multiple myeloma]] |
||
** [[Thyroid cancer]] |
** [[Thyroid cancer]] |
||
** [[Non-Hodgkin lymphoma]] |
** [[Non-Hodgkin lymphoma]] |
||
+ | ** [[Non-small cell lung cancer]] |
||
+ | ** [[Langerhans cell histiocytosis]] |
||
* Mixed lesions |
* Mixed lesions |
||
− | ** |
+ | **[[Breast cancer]], though it is predominantly osteolytic |
** [[Colorectal cancer]] and other gastrointestinal cancers |
** [[Colorectal cancer]] and other gastrointestinal cancers |
||
** [[Squamous cell cancer]] |
** [[Squamous cell cancer]] |
||
Line 21: | Line 24: | ||
* [[Denosumab]] at high dose |
* [[Denosumab]] at high dose |
||
* [[Bisphosphonate]] |
* [[Bisphosphonate]] |
||
+ | |||
+ | == Further Reading == |
||
+ | |||
+ | * Bone Metastases: An Overview. ''Oncol Rev''. 2017 Mar 3; 11(1): 321. doi: [https://doi.org/10.4081/oncol.2017.321 10.4081/oncol.2017.321] |
||
[[Category:Oncology]] |
[[Category:Oncology]] |
Revision as of 12:01, 26 August 2021
Differential Diagnosis
- Osteoblastic (sclerotic) lesions, with deposition of new bone
- Osteolytic lesions, with destruction of normal bone
- Mixed lesions
- Breast cancer, though it is predominantly osteolytic
- Colorectal cancer and other gastrointestinal cancers
- Squamous cell cancer
Management
- Denosumab at high dose
- Bisphosphonate
Further Reading
- Bone Metastases: An Overview. Oncol Rev. 2017 Mar 3; 11(1): 321. doi: 10.4081/oncol.2017.321